By Dean Seal


Tiziana Life Sciences has gotten regulatory clearance for its investigational new drug application covering a potential Alzheimer's disease treatment.

The biotechnology company said Tuesday that the U.S. Food and Drug Administration has cleared the application for intranasal foralumab to be studied in Alzheimer's disease.

Foralumab could be a groundbreaking new treatment for Alzheimer's as it targets the disease's underlying pathology by addressing the resulting neuroinflammation caused by the accumulation of toxic proteins in the brain, Tiziana said.

"Foralumab shows great promise in targeting the pathological hallmarks of the disease, and I am optimistic about its potential to offer a breakthrough treatment option for patients suffering from this devastating condition," said Professor Howard L. Weiner of Harvard Medical School.

Shares jumped 22% to 73 cents in premarket trading.


Write to Dean Seal at dean.seal@wsj.com


(END) Dow Jones Newswires

08-15-23 0731ET